High drug loads of nanoparticles are essential to efficiently provide a desired dosage in the required timeframe, however, these conditions may not be reached with so far established degradable matrices. Our conceptual approach for increasing the drug load is based on strengthening the affinity between drug and matrix in combination with stabilizing drug-matrix-hybrids through strong intermolecular matrix interactions. Here, a method for designing such complex drug-matrix hybrids is introduced employing computational methods (molecular dynamics and docking) as well as experimental studies (affinity, drug loading and distribution, drug release from films and nanoparticles). As model system, dexamethasone (DXM), relevant for the treatment of inflammatory diseases, in combination with poly[(rac-lactide)-co-glycolide] (PLGA) as standard degradable matrix or oligo[(3-(S)-sec-butyl)morpholine-2,5-dione]diol (OBMD) as matrix with hypothesized stronger interaction with DXM were investigated. Docking studies predicted higher affinity of DXM to OBMD than PLGA and displayed amide bond participation in hydrogen bonding with OBMD. Experimental investigations on films and nanoparticles, i.e. matrices of different shapes and sizes, confirmed this phenomenon as shown e.g. by a~10 times higher solid state solubility of DXM in OBMD than in PLGA. DXM-loaded particles of~150 nm prepared by nanoprecipitation in aqueous environment had a drug loading (DL) up to 16 times higher when employing OBMD as matrix compared to PLGA carriers due to enhanced drug retention in the OBMD phase. Importantly, drug relase periods were not altered as the release from films and particles was mainly ruled by the diffusion length as well as matrix degradation rather than the matrix type, which can be assigned to water diffusing into the matrix and breaking up of drug-matrix hydrogen bonds. Overall, the presented design and fabrication scheme showed predictive power and might universally enable the screening of drug/matrix interactions particularly to expand the oligodepsipeptide platform technology, e.g. by varying the depsipeptide side chains, for drug carrier and release systems.
Introduction
The design of polymeric nanocarriers often faces challenges when it comes to desired high drug loadings, particularly when phase distribution phenomena during particle preparation enable drug leakage as typically is the case for emulsion or nanoprecipitation techniques in aqueous media [1] . While changing the ultrastructure of particles, e.g. impermeable materials, may allow retaining drug in the polymer phase, release pattern may be altered or delayed, which is effecting the efficacy of carriers modified in such way. Depending on the respective clinical application ranging from local delivery into skin to systemic application of nanoparticles, the characteristica of the carrier's matrix system may need to be tailored for the respective drug compound [2] . Therefore, a computer-assisted method is desirable that allows the design and/or selection of complex novel matrix materials with increased drug loading (DL) while not necessarily changing the drug release kinetic. The conceptual design of such a complex material system will have to consider the different hierarchical levels of organization of a polymer-drug hybrid and models of drug loading as well as of drug release by employing theoretical as well as experimental approaches (Fig. 1 ).
DL and release are both related to physical interactions between the drug and the matrix [3] , while contributions of solvent molecules will play an important role particularly during release. The affinity between a specific drug and a carrier is affected by the chemical structure of the selected polymer and the presence of chemical functional groups enabling e.g. hydrophobic interactions [4] , π-π interactions, electrostatic interactions, or hydrogen bonds (H-bonds) [5, 6, 7] .
The strength of the interaction established between a drug and a matrix can be predicted by computational studies [8] and explored by means of experimental approaches. In case of polymer-drug interactions, Molecular Dynamics (MD) simulations are usually helpful in defining different polymer conformations that can afterwards be employed in docking studies to calculate the binding affinity of drug and polymer as well as the relative orientation of the binding partners. Such approaches may correlate to experimental results [9] , where a higher binding affinity indicated by more negative binding energies corresponded to higher experimental DL [10, 11] . Experimental methods include on the one hand the solution state, e.g. the drug solubility or stabilization/destabilization of a supersaturated drug solution upon addition of polymer [12, 13] . On the other hand, the solid-state solubility of the drug in the polymer matrix can be investigated [14, 15] .
(Co)polyesters, with PLGA as main protagonist, are a typical choice for polymeric drug release systems, as they combine easy (also commercial) accessibility, favourable toxicological profiles, and compatibility with many drugs and applications [16] [17] [18] . If sterically possible, PLGA may engage in hydrophobic interactions as well as form hydrogen bonds between the ester bond and -OH-groups of hydrophobic drug molecules like dexamethasone (DXM). DXM is used here as a model compound with a high application relevance for the treatment of inflammatory diseases, e.g. of the skin, joints, and the eye. Drug transport and release are required for effective and safe treatment with DXM [19] . However, PLGA cannot build physical links to H-bond acceptor groups of drugs such as DXM due to its lack of H-bond donor sites.
In this study, oligo[3-(S)-sec-butylmorpholine-2,5-dione]diol OBMD as representative of the oligodepsipeptide (ODP) family [20, 21] was hypothesized as matrix material alternative due to its availability of amide bonds in the backbone as H-bond donor sites. The suitability of this material and the selection approach should be demonstrated including both the molecular interaction for enhanced drug loading determined by computer-assisted design and experimental model studies on the morphology of drug carriers of different sizes/shapes (nanoparticles/films) and their associated loading and release behaviour.
Fig. 1.
Conceptual design for studying novel drug-matrix hybrid systems. Drug matrix interactions can be predicted by computer-assisted methods employing molecular dynamics calculations and docking, and experimentally explored by determining the drug solubility in the presence of the matrix polymer. In the experimental set-up, in addition to the interaction of drug and matrix molecules, interactions of the drug with the solvent as well as to other drug molecules influence the solubility. The morphology of drug matrix hybrids may consist of the matrix with molecularly dissolved drug or of a system, in which drug aggregates occur and are more or less homogeneously distributed. Experimental evaluation by methods such as Raman spectroscopy, electron microscopy or wide angle X-ray scattering help to clarify the morphology. In this study, two types of shaped bodies were investigated. In films, drug loading by co-dissolution and solvent evaporation leads to a predetermined loading, though it may result in differing morphologies depending on the drug content. In particle preparation, the affinities of drug to the polymer matrix as well as drug to solvent influence the final loading. Drug release is depending on the drug diffusion, water uptake, diffusion lengths as well as potentially the polymer degradation.
Materials and methods

Materials
Oligo[3-(S)-sec-butylmorpholine-2,5-dione]diol (OBMD) (M n(NMR) = 4.5 and 5 kDa, PDI = 1.2) was synthesized via ring opening polymerization according to Ref. [22] . In short, a freshly prepared 0.3 M solution of Sn(Oct) 2 in anhydrous THF was transferred into a dry Schlenk tube, followed by the solvent removal under high vacuum. Thereafter, 1,8-octanediol and 3-((S)-sec-butyl)morpholine-2,5-dione) were added, several evacuation-nitrogen refill cycles were performed and the tube was placed in a preheated oil bath at 135°C. The polymerization was ceased by the addition of chloroform. The product was purified by triple precipitation from chloroform in diethyl ether and dried under vacuum.
Poly[(rac-lactide)-co-glycolide] (PLGA; Resomer RG502, lactide to glycolide molar ratio 50:50, M n (GPC) = 6 kDa, PDI = 1.8) was purchased from Boehringer-Ingelheim (Germany).
Four-armed star-shaped oligo(ethylene glycol) with a M n(Maldi-TOF) = 10.2 functionalized with desaminotyrosine (sOEG-DAT) (degree of functionalization (d.f.) = 69%) were synthesized according to Ref. [23] . In short, DAT, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and N-hydroxysuccinimide were dissolved in NMP at −5°C, followed by addition of N,N-diisopropylethylamine. In a second flask, sOEG was dissolved in NMP at −5°C. Thereafter, both solutions were combined and the reaction mixture was stirred for 16 h. The obtained polymer was precipitated in a mixture of n-hexane and ethyl acetate, filtered and washed with ethyl acetate. The material was dissolved in a small amount of water and freeze dried in order to obtain the final product. Trifluoroacetic acid (≥99%) was bought from Honeywell (Germany). Dexamethasone (DXM) (≥98% (HPLC), powder, T m = 262-264°C) (Sigma-Aldrich, Germany) was kindly provided through the DFG-CRC 1112. Formic acid (Optima LC/MS grade) was purchased from Fisher Scientific (Belgium).
Methods
Computational studies
Three dimensional structures and molecular dynamics (MD) simulations of OBMD, PLGA and DXM were generated by using Ascalaph Designer (Agile Molecule). The chemical structure of both oligomers was composed of 9 dimer repeating units. Three different conformations were investigated for both oligomers: (i) a linear conformation obtained by only optimizing the geometry of the hand-drawn molecules, (ii) a random non-linear conformation defined by MD simulations performed at T = 500 K until a folding of the linear structure was visualized (non-specific timeframe) and (iii) a non-linear defined conformation delineated by MD simulation performed at T = 500 K with time step of 0.5 fs and a duration of 20 ps. The MD simulations have been carried out using AMBER 94 as force field and with explicit water. Thereafter, DXM was docked into the oligomer conformations using AutoDock Vina [24] software package (The Scripps Research Institute). The visualization of the intermolecular interactions and the figures for this article were prepared using AutoDock Tools (ADT) [25] .
Evaluation of drug solubility in acetone
The solubility of DXM in acetone with or without the presence of different amounts (1, 10, 50, 100, 200 and 400 mg/mL) of oligomers (PLGA or OBMD) was determined by adding the organic solvent stepwise to the vial containing a known amount of DXM. After each addition, the vial was weighted and shaken up to 30 min. The solvent addition was stopped when all DXM was dissolved, which could optically been detected as disappearance of the drug powder and of the milky color of the mixture. For each oligomer amount, the experiment was repeated at least in triplicate.
Film preparation
PLGA or OBMD and DXM were added to acetone in order to obtain solutions with an oligomer amount of 400 mg/mL and having 0.5, 1 and 2 wt% of DXM (relative to the oligomer). 250 μL of each solution were spread on a glass microscope slide, which was previously silanized by treatment with dichlorodimethylsilane in toluene (5 vol%) in order to promote the removal of the dry film from the glass. The solvent was allowed to evaporate overnight at room temperature. The remaining acetone was removed by first drying the films in the oven at 50°C for 5 h, followed by drying under vacuum (ca. 10 mbar) at room temperature overnight and afterwards at higher vacuum (0.1 mbar) for 5 h. Similarly, films using OBMD and PLGA solutions having 10 mg/mL oligomer concentration and 1, 2, 10, 20 and 50 wt% of DXM (relative to the oligomer) were prepared by pouring 5 mL of the solution in a 5 mL beaker and by evaporating the solvent as previously described.
WAXS analysis
Wide-angle X-ray scattering (WAXS) measurements [26] were conducted on a Bruker D8 Discover X-ray diffractometer in transmission geometry using a X-ray generator operated at 40 kV and 40 mA on a copper-anode. The collimator was set to 0.8 mm (beam size). The twodimensional detector (Hi-Star) was operated in 1024*1024 pixel mode. The distance sample-detector was 150 mm and the wavelength λ = 0.15418 nm. The detector was positioned at angular positions 2θ = 20°in order to cover an angular range from 2θ = 4°to 36°. Exposure time was 240-600 s to yield a total of~5,000,000 counts. Integration of I vs 2θ was performed to determine peak positions.
Raman analysis
Surface compositions were analyzed with a confocal Raman microscope SENTERRA (Bruker Optik GmbH, Ettlingen Germany), performing the measurements at room temperature with a 532 nm laser source at a power of 10 mW in the general spectral range of 70-3700 cm −1 at a resolution of 2 cm −1 using an objective with magnification of 50×. The charge-coupled device (CCD) exposure time was 1 s, and an average of 128 cycles was used to increase signal-to-noise ratio. Samples were fixed on computer controlled xyz stage allowing increment stepping down to 0.1 μm in all directions. Spectra analysis was performed with OPUS software (version 7.5, Bruker Optik GmbH, Ettlingen Germany). First survey spectra on pure DXM and pure polymer films were measured over the whole spectral range. For the Raman mapping experiments, a smaller wave number range of 1516 to 2740 cm −1 was used, where both components show characteristic frequencies. In general, the mapping experiments were performed for square grids of 40 × 40 µm 2 with a distance of about 2 μm in x-and ydirection.
Thermal transitions studied by DSC
The thermal transitions of the oligomers were determined by differential scanning calorimetry (DSC) using a Netzsch DSC 204 (Selb, Germany). The experiments were conducted by heating the sample from 0°C to 200°C, then cooling down to −50°C, and again warming up to 200°C with a constant heating and cooling rate of 10 K·min −1 . In the case of samples to which water was added, the upper temperature in the first heating run was 80°C. The glass transition temperature (T g ) was determined from the second heating run for the dry samples, and from the first and second heating runs from the samples containing water. Experiments were performed once.
SEM (EDX) analysis of particles and films
The particle morphology was analyzed by Scanning Electron Microscopy (SEM) using a Zeiss Gemini Supra 40 VP microscope with a Scottky emitter at an acceleration voltage of 3 kV. The samples were spattered with Iridium (4 nm layer) with a Polaron SC7640 sputter coater (Quorum Technologies Ltd., UK). SEM images of the films were performed using carbon as conductive coating layer, an acceleration voltage of 10 kV and material contrast imaging (back scattered electrons). The elemental composition of the films was studied by energydispersive X-ray (EDX) spectrometry using an EDAX Detecting Unit PV7715/89-ME (Ametek GmbH), which was coupled to the SEM instrument.
Drug release from film
The OBMD and PLGA films were prepared from a solution containing 400 mg/mL oligomer concentration and 1 wt% DXM (relative to oligomer) by casting and drying. The glass slides with attached films were cut to obtain rectangular shaped film samples of 1 × 0.8 cm. Three samples for each film were cut. Each sample was placed in a vial containing 12 mL of phosphate buffer saline (PBS, pH 7.4) and subjected to shaking at 600 rpm using an orbital shaker (DITABIS, Pforzheim, Germany). At certain intervals of time, 0.2 mL of the medium were collected and replaced with fresh PBS solution. The DXM concentration was quantified by ultra-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (UPLC-ESI-MS). The UPLC system was an Ultimate 3000 (ThermoScientific, USA). The reversed phase analysis was performed using an Acclaim™ RSLC column (pore diameter 120 Å, particle size 2.2 μm, C18; Thermo Scientific, USA) at a column temperature of 30°C coupled with UV/VIS detector. 
Particle preparation by nanoprecipitation
A precipitation technique was employed to prepared OBMD and PLGA particles. Briefly, OBMD or PLGA (50 mg) were dissolved in 20 mL of acetone. The solution was added dropwise into 25 mL of surfactant (sOEG-DAT) solution in water (0.05 wt%), while the aqueous phase was mixed by means of a magnetic stirrer. Drug-loaded particles were prepared by co-dissolving the desired amount of DXM (5-30 mg) in the acetone solution. Afterwards, the organic solvent was evaporated by stirring the solution for 5 h. The suspension was filtrated with a 40 μm filter (nylon cell strainer, neoLab GmbH, Heidelberg, Germany) in order to remove non-encapsulated DXM crystals formed during solvent evaporation. All experiments were repeated at least in triplicate.
Particle size and zeta potential characterization
The hydrodynamic diameter (D h ) and the polydispersity index (PDI) of the particles were determined by Dynamic Light Scattering (DLS) using ZetasizerNano SZ instruments (Malvern, Worcestershire, UK). The measurements were performed at 25°C with a He-Ne laser operating at 633 nm, detecting the scattered light at an angle of 173°. Each sample was measured three times with 10 sub-runs each time. The zeta potential was determined using the same instrument measuring at 25°C. Each sample was analyzed in triplicate with manifold runs (10 to 100 depending on instrument standards).
Drug loading evaluation
2 mL of the particle suspension were centrifuged at 14000 rpm for 10 min to separate the loaded particles from free DXM followed by washing 2 mL of water, centrifugation and lyophilization. The dried, balanced particles were dissolved in 0.6 mL of acetonitrile. Then, 1.4 mL of water was added in order to precipitate the particle matrix and keep DXM dissolved in the supernatant. After centrifugation, the DXM concentration was quantified by High-Performance Liquid Chromatography (HPLC) using a Dionex Ultimate 3000 system (Dionex Softron GmbH, Germering, Germany) with UV detection (240 nm). A LiChrospher® 100 RP-18 (5 μm) LiChroCART® 125-4 (Merck Chemicals GmbH, Darmstadt, Germany) column was used and the mobile phase consisted of 65% water with 0.1% TFA and 35% acetonitrile at 1 mL·min −1 .
The drug/dye loading (DL%) was calculated according to eq. (1).
DL (%)
Mass of drug/dye encapsulated Mass of loaded particles 100 =
The encapsulation efficiency (EE%) was calculated according to eq. (2).
EE (%)
Mass of drug encapsulated Mass of theoretical drug payload 100 =
In vitro release kinetics of DXM from PLGA and OBMD particles
In vitro release studies of DXM from the particles were performed by dialysis at 37°C, ensuring sink conditions in the acceptor medium. A known amount of particles was suspended in 2 mL of PBS (pH 7.4) and placed into a Pur-A-Lyzer maxi dialysis membrane (regenerated cellulose, cut off 50 kDa). The samples were each introduced in separate vials with 16 mL of PBS and subjected to shaking at 600 rpm using an orbital shaker (DITABIS, Pforzheim, Germany). Three vials were prepared for each particle type (OBMD and PLGA particles). At certain intervals of time, 2 mL of the medium were removed and replaced with fresh PBS solution. The taken medium was analyzed by HPLC to determine the DXM concentration.
Statistical evaluation
Statistical evaluation to determine significant difference when comparing different groups of data was carried out by two-tail t-test (in the case of the comparison between two groups of data) or one-way Anova analysis (in the case of comparison between three or more groups of data (significant difference at p-value: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001)), using Graphpad Prism as software. The statistical evaluation was performed for those experiments that have been repeated at least in triplicate (n ≥ 3). If not specified differently, data are shown as average value ± standard deviation (SD).
Results and discussion
Oligodepsipeptide for enhanced drug interaction compared to PLGA
ODPs are oligomers having an alternating sequence structure consisting of α-hydroxy and α-amino acids based repeating units. Thus, ODPs like OBMD display both ester and amides linkages in their backbone, compared to polyesters like PLGA as a standard matrix for (nano)particulate drug carriers having only ester junctions. The amide bonds in the OBMD chain may act as H-bond donors and have therefore a potentially increased capability to engage in H-bonding to DXM, a therapeutically relevant compound used here as a model drug, compared to polyesters, that only contain H-bond acceptors (Fig. 2a-b) .
OBMD with its sec-butyl side chain was chosen since increasing side chain volume has been connected to stabilization of secondary structures [27, 28] . While being considered as a hydrophobic material, water is expected to penetrate into bulk OBMD and interact with the polymer backbone through hydrogen bonding, thus competing with drug molecules at their binding sites during release conditions. In order to compare the two different materials, similar molecular weights were selected (M n OBMD = 5 kDa; M n PLGA = 6 kDa). Although PLGA with a M n = 6 kDa is an oligomer following the IUPAC definition [29] , it is commonly accepted to refer to it as poly[(rac-lactide)-co-glycolide] (PLGA).
As a first step in a rational design approach, a computational study was conducted to predict the molecular interactions between the drug and the two matrices. For this purpose, molecular models of the matrices and DXM were constructed in order to have a more realistic representation of the conformations that the oligomer chains are adopting in solution. This step is of importance because potential drug-matrix interactions depend not only on the presence of functional groups, but on their spacial position and thus availability for interactions. For both matrices, one linear conformation and two non-linear conformations as obtained after MD simulations were studied (Table 1) , while one conformation of DXM was employed due to its rigid structure. The subsequent docking analyses showed more negative calculated free binding energy of DXM with OBMD compared to PLGA when comparing similar conformations of the oligomers (Table 1) . In accordance with the hypothesis, this computational analysis suggested that amide bonds in the OBMD backbone can interact with the carbonyl group of DXM by H-bonds, which is not the case for PLGA due to a lack of H-bond donors (Fig. 2 c-d) . It should be noted that DXM demonstrated lower binding energies for the non-linear conformations compared to an extended, quasi linear one ( Table 1) , and that such nonlinear conformations are more likely adopted in solution than extended ones. Overall, based on the Gibbs equation, this analysis suggested higher binding affinity, namely lower dissociation constant (K D ), of DXM (here the ligand) to OBMD than to PLGA and supported further experimental analysis of OBMD as drug carrier.
Strategy to form polymer-drug composites
In order to experimentally form drug loaded polymer matrices, such as nanoparticulate matrices, conditions have to be selected, at which the molecular interactions suggested above could actually take place. This may be the case for solutions, in which drug and polymer are codissolved, i.e. molecularly dispersed, or at least highly swollen (at high polymer concentrations) thus allowing suitable spatial flexibility to adapt preferred (chain) conformations.
A solvent should be selected, which is suitable for later formulation of drug loaded nanoparticles via an emulsion or nanoprecipitation technique, but at the same time allows for model studies to characterize the formation of drug-polymer composites. Accordingly, the solvent had to fulfill the following prerequisites: 1) ability to dissolve the polymers and the drug, 2) low boiling point for solvent evaporation and formation of solid matrix, and 3) acceptance for pharmaceutical applications. Based on these criteria, candidate solvents were acetone, chloroform and ethanol, while dimethylsulfoxide and 
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dimethylformamide were neglected due to their higher boiling points. Out of these, acetone was preferred as only a low DMX solubility in chloroform (~1 mg/mL) and a low PLGA solubility in ethanol (< 20 mg/mL) were measured. In contrast, acetone allowed a DXM solubility of 13-14 mg/mL and a PLGA solubility > 400 mg/mL. OBMD solutions in acetone started to become slightly turbid at oligomer concentration > 100 mg/mL, suggesting that the oligomer was not completely dissolved in the solvent at these concentrations. In the next step, the co-dissolution of drug and polymer was investigated, which provided further insights for solvent selection, while at the same time indicating whether the combination of the components provides stabilization of the respective solution through molecular interactions. In vials containing a known amount of DXM, acetone was added step-wise with or without the presence of the oligomer until an optically clear solution (dissolution of DXM powder) was observed. The presence of OBMD significantly increased the drug solubility in acetone from 13.8 mg/mL up to 15.9 ± 0.3 mg/mL at an OBMD concentration in acetone of 100 mg/mL (Fig. 3) . Moreover, at OBMD concentrations of 200 and 400 mg/mL (OBMD highly swollen but not completely dissolved) DXM solubility further increased (data not shown). This behavior underlined that in the selected solvent, OBMD chains show sufficient flexibility to adapt conformations that enable physical interactions with DXM for increased solubility. Also previously polymer-drug interactions have been attributed to enhance the drug supersaturation equilibrium, though the mechanism may not have been fully clarified [30] . In contrast to the findings with OBMD, the solubility of DXM was only slightly and non-significantly increased to 14-14.5 mg/mL at all tested PLGA concentrations (Fig. 3) .
Conceptually, a drug-polymer solution with a mutually supported equilibrium solubility of both compounds will be subject to molecular reorganisation when the solvent is removed such as by extraction into an aqueous phase or evaporation into a gas phase. At a low drug content relative to the polymer matrix, the drug may remain molecularly dissolved (now in the amorphous polymer phase) depending on the ability to form molecular interactions in the solid state, while drug aggregates are expected to occur at higher drug contents leading to composites. The drug/matrix ratio, at which a change from molecularly dissolved state to drug aggregates occurs is correlating with the drug-matrix affinity. Still, the nature of those aggregates may differ depending on the interactions possible at phase boundaries of drug and polymer. They may either be well dispersed in the matrix or may form larger layers or other shapes of drug phases clearly separated from the polymeric material. A further point to consider is that stronger polymer-polymer interactions may increase the drug loading capacity of a composite matrix in any of these morphologies just by stabilizing the composite against disintegration. Characterizing composite matrices formed from solutions of increasing drug-to-polymer ratios will allow concluding on the morphologies adapted in the solid state. Elemental analysis in electron microscopy (SEM-EDX) or X-ray scattering (WAXS) techniques are thus approaches to analyze composite characteristics and conclude on molecular interactions in carrier systems in the absence of solvents (including absence of water).
Carrier matrices and drug-polymer hybrid morphology
As carrier matrices, nanoparticles of~150 nm, i.e. matrices with a high surface to volume ratio, were selected. When the loading is performed simultaneously to the particle formation by nanoprecipitation involving solvent (and drug) flux in aqueous environment, drugpolymer-affinities are critically ruling the drug loading of the particle. As a different shape, films of~150 μm thickness prepared by solvent casting were included, also making the material system assessible for morphological analysis by SEM-EDX and WAXS.
The preparation of polymer films from acetone solutions was conducted with two fixed polymer concentrations (10 mg/mL; 400 mg/mL) and an increasing amount of DXM in acetone solutions. Only limited DXM loadings up to 2 wt% could be explored for 400 mg/mL polymer solutions because of the limited solubility of DXM in these PLGA/ acetone solutions. Higher DL, up to 50 wt%, have been reached using the 10 mg/mL oligomer concentration. This approach allowed not only to form films of diffent drug loadings, but also to investigate the solidstate solubility of the drug in the different matrices. This adds information to the above reported investigation of drug-polymer interaction in solution: If the affinity of a drug to a polymer is low, the drug molecules prefer to interact with each other, instead of interacting with the polymer chains. This leads to the formation of drug aggregates, which can be visually detected by evaluating the transparency of the drug-loaded films [31] and indicate that the solid-state solubility of the drug has been exceeded.
In case of PLGA, a precipitation of drug was detected at a DXM loading of 2 wt%, while all investigated DXM-loaded OBMD films were transparent (Fig. 4a-b) . This first optical analysis suggested that the saturation solubility of DXM was lower in PLGA (between 1 and 2 wt%) compared to OBMD (> 2 wt%). WAXS analysis conducted to investigate drug aggregate morphology suggested absence of crystalline drug even in the case of the PLGA film loaded with 2 wt% DXM, i.e. indicating the drug aggregate phase to be in an amorphous state (Fig. S1, Supporting information) . Interestingly, the OBMD matrix itself was not completely amorphous as shown also for unloaded OBMD film with WAXS peaks at 2θ = 8.0°and 20.0°due to oligomer chain arrangment in a secondary structure. The scattering peak at 2θ = 8.0°corresponded to a repeating distance of 11 Å and was comparable to the peak detected for PIBMD at 2θ = 8.8° [32] . Oligodepsipeptides, which are composed of a perfectly alternating sequence structure, have been described to adopt concatenated ribbon or helical structures, but no α-helical structure [20] . Stabilization of a matrix, in which the individual macromolecule adopts helical structures requires intermolecular interactions. It should be noted that the observed repeating distance has been reported also for interstrand contacts e.g. in collagen [33] showing such intermolecular stabilization. Upon addition of DXM to OBMD films, a broadening of the WAXS peak detected in the range of 2θ = 6-9°suggested that the oligomer chains were engaged in interactions with the drug, which resulted in a diminution of the interchain interaction and, therefore, a less organized OBMD structure.
Raman spectroscopy has been used to analyze the drug distribution in the films and to verify if the white spots formed in PLGA films with 2 wt% DXM loading corresponded to DXM aggregates. In agreement with visual inspection, the Raman mapping of films loaded with 0.5 and 1 wt% DXM showed a homogeneous DXM distribution, while DXM aggregates were clearly detected in PLGA at 2 wt% DXM loading (Fig. 4c) . The mapping suggested a partial phase separation of DXM from the PLGA matrix probably caused by the weak interactions between the drug and PLGA. In contrast, DXM was homogeneously distributed in OBMD also at 2 wt% DXM loading (Fig. S2, supporting  information) .
SEM-EDX analysis of sample cross sections used fluorine atoms to localize DXM as the element distinctive of DXM versus polymer. In this way, the white spots in PLGA film with a 2 wt% DXM loading could be confirmed to be DXM (Fig. 4d) . SEM analysis of OBMD films also showed some light gray spots; however, EDX analysis did not detect higher fluorine concentrations in these regions but higher oxygen and lower nitrogen and carbon contents. These spots could be assigned to glass fragments resulting from cutting the OBMD films attached to a glass support. Thus, SEM-EDX confirmed that OBMD film with 2 wt% DXM had a homogeneous drug distribution.
In order to investigate the maximum solid state solubility of DXM in OBMD, film samples were prepared by solvent evaporation using 10 mg/mL solutions of polymer/oligomer with 1, 2, 10, 20 or 50 wt% DXM relative to the matrix material. Also under these conditions, DXM aggregates visible as white spots were detected for PLGA at loadings ≥2 wt% (Fig. S3, supporting information) , suggesting that this solid state solubility limit is independent from preparation paramters such as initial oligomer concentration. For OBMD films, white DXM aggregates were noticeable at loadings ≥20 wt%, i.e. in the range of one order of magnitude higher compared to PLGA. SEM-EDX analysis (Fig. S4a-b , supporting information) confirmed these morphological differences of DXM loaded PLGA and OBMD.
The experimental results described above supported the computational prediction by demonstrating that, in both the dissolved state and the solid state, OBMD showed the capability of engaging in stronger interaction with DXM compared to PLGA. It should now be confirmed that this principle is relevant also for achieving higher drug loadings in nanoparticles, where the presence of an additional aqueous phase with distinct DXM solubility is highly contributing to drug loss during particle formation/hardening. By a nanoprecipitation technique, OBMD and PLGA submicron particles having mean hydrodynamic diameters (D h ) ranging from 130 nm to 170 nm were successfully formed in both drug-free conditions and at different DXM/Polymer (D/P) ratios (mg/ mg) (Fig. S5a, supporting information) . All particle suspensions showed a narrow size distribution, with polydispersity indices (PDI) ranging between 0.07 and 0.13. SEM images confirmed the size range and narrow size distribution determined by DLS and showed that the particles were round shaped (Fig. S5b, supporting information) .
Due to a flux of freely water-miscible acetone from the polymer phase to the continuous phase used in nanoprecipitation techniques, codissolved drugs with (partial) water solubility typically follow the solvent flux eventually resulting in low encapsulation efficiency (EE). This can be seen for PLGA nanoparticles, where the mean EE was below 1% for all D/P ratios. In contrast, as a consequence of the enhanced molecular interaction, much higher EE were obtained for OBMD formulations, e.g. 14 wt% at a D/P ratio of 0.1 (Table 2) . Importantly, for all formulations tested, OBMD reached values of final drug loading (DL) in the range of~2 wt%, while PLGA depicted DL of only~0.1 wt%. Statistical analysis confirmed these differences to be highly significant (D/P 0.1 and 0.2: p < 0.0001; D/P 0.4 and 0.6: p < 0.05). The DL was, in both systems, not directly correlating with the amount of DXM used in the formulations, suggesting that a plateau level of payload that is specific for the respective material can be achieved. Overall, the hypothesis of enabling higher DL in OBMD-based nanoparticles due to enhanced molecular interactions can be supported by these experimental data. Even though the preparation of films and particles differ, the higher solid state solubility of DXM in the OBMD matrix translated into higher particle drug loading, which fits to further studies in the literature [31] .
In order to gain more morphological insights in polymer/drug hybrid morphology for the submicron particles, WAXS analysis was conducted also on particle powders. The peak detected at 2θ = 6-9°in OBMD particles supported stabilizing intermolecular interactions, which were already detected in the OBMD films. The DXM reflections in both OBMD and PLGA particles had a pronounced spot-like character, which indicated DXM aggregates (Fig. S6, supporting information) and, therefore, suggested that the DXM distribution in the particles was not homogeneous. The more intense and larger number of spots in case of the OBMD particles than in the PLGA particles correlated with the higher loading. The peaks at 2θ = 14°for both particle matrices together with the one at 2θ = 17°for OBMD particles indicated that the DXM aggregates are in the crystalline form in both particle types.
It can be assumed that the presence of intermolecular interactions also supports the stabilization of the nanoparticle, which thus might be capable to encapsulate a higher amount of drug without impairing nanoparticle integrity e.g. by a pronounced phase separation of drug and polymer. Therefore, the higher DL detected in OBMD particles is probably not only due to the stronger interaction between the oligomer and the drug molecules and crystal interfaces, but may be supported by oligomer-oligomer interactions that permit to host a higher number of crystals while ensuring the integrity of the matrix.
Drug release features
In order to investigate whether the different affinities between drug and the two matrix materials would also result in a different release kinetics, DXM release studies were performed from films and nanoparticles.
The release from 150 μm thick films of 1 × 0.8 cm connected at one side to a glass support was investigated at 1 wt% DXM loading for both PLGA and OBMD so that all samples contained homogeneously distributed DXM. During the 45 days of release study, changes in the film sample shape took place. At day 21, all samples had detached from the glass and assumed a spherical shape (Fig. S7, supporting information) . This phenomenon may be assigned to viscous flow of the hydrophobic polymer towards reduced interfacial areas, considering that the materials may be partially plasticized in the presence of water at 37°C (T g,onset PLGA =~26°C, T g,onset OBMD =~34°C; Supporting Fig. S8 ) and slowly undergo hydrolysis as associated with a further decrease in T g .
The cumulative release showed that the release of DXM from OBMD films was slower than for PLGA films, most obvious at time points > 14 d (Fig. 5a ). Such slow release of dexamethasone can be of interest when implants are permanently placed in the body and foreign body response should be reduced [34] . This delay in the drug release suggests that at large matrix sizes, here films with a thickness of~150 μm transforming into spheres of an even larger internal drug diffusion length with time, the stronger drug-matrix interaction in OBMD and the known slower degradation of OBMD compared to PLGA promote a delay in release. Indeed, starting from day 28, a size reduction of the PLGA spheres could be observed and at the end of the study (day 45), only~3 mg of PLGA compared to~11 mg OBMD could be recovered from the respective vials (initial weight:~11-12 mg). The formation of acidic degradation products from PLGA [35] was also proven by a decrease of the pH in the release media (Fig. S9, supporting information) , illustrating the contribution of faster degradation of PLGA to DXM release from films. Importantly, drug quantification has to be performed with techniques confirming drug integrity. For this purpose, UHPLC-ESI-MS was employed using the extracted ion chromatogram (EIC) at MW = 393.2 ± 0.3. The DXM portion extracted from OBMD films showed three additional peaks at different retention times (Fig. S10 , supporting information) with the same isotopic patterns (Fig. S11,  supporting information) . By molecular fragmentation, the same fragmentation patterns were detected in all the peaks (Fig. S12 and S13, supporting information). The characteristic fragments detected for pure DXM, as reported also in previous studies (e.g. fragments at MW of 147, 237, 337 and 355 m/z) [36] [37] [38] [39] , were also observed in the fragmentation pattern of these so far unassigned additional UHPLC-ESI-MS peaks. These results suggested that the side peaks with enhanced retention time were caused by another molecule interacting with the drug/ column rather than chemical modification of the drug.
Interestingly, in the first two weeks of release before a major contribution of matrix degradation can be assumed, the two matrix materials released the same percentage of DXM but followed slightly different kinetics as investigated by various kinetic models: zero order, first order, Higuchi, Korsmeyer-Peppas and Hixon-Crowell models (Table S1 , supporting information). In the case of PLGA films, highest correlation coefficients were observed for the zero order kinetics model, as also reported before for the phase prior to onset of degradation effects [40, 41] . For OBMD, highest correlation coefficients were obtained with the Korsmeyer-Peppas model with a release exponent of 0.44, which in the case of films indicates a Fickian diffusion. Accordingly, DXM release in OBMD films was controlled by the molecular diffusion of the drug due to a chemical potential gradient and was not influenced by changes of the matrix [42] .
When drug release was explored for DXM loaded nanoparticles, samples prepared with D/P ratio of 0.1 were selected as these had highest EE. The DXM release kinetics were comparable in both the matrices (Fig. 5b) with almost 90 wt% drug released in the first 24 h, which compares to literature data of DXM-loaded PLGA particles releasing > 90 wt% drug in 4 h [43] . When fitting the release profiles with kinetic models, correlation coefficients were poor (< 0.8) indicating that the experimental data cannot be appropriately described by any of these models. Thus, drug release from such small dimension matrices was not mainly controlled by diffusion barriers originating from the polymer material, but may be linked to dissolution/phase distribution of drug located in proximity to the particle surface [44] .
The congruent DXM release profiles for OBMD and PLGA nanoparticles irrespective of the much stronger initial drug-polymer interaction and higher DL can be of particular interest when a relatively high drug concentration is required for a therapeutic effect [44] , or where contact times of drug carrier and target tissue is limited [45] . Conceptually, this pattern has been achieved by facilitating the influence of water on matrix organization and, similarly, on the drug-matrix interactions. While multiple DXM-OBMD interactions occur via hydrogen bonding apparently in both acetone solutions and solid state, numerous water molecules compete with these intermolecular interactions during release conditions. Furthermore, during release at 37°C compared to particle preparation at 25°C, H-bond strength between drug and Table 2 ) in PBS buffer (n = 3, mean, SD). polymer can be expected to decrease as such bonds are inversely proportional to temperature [46] . A method very sensitive towards changes in matrix properties upon water uptake is DSC, which clearly illustrated a reduction of T g of OBMD powder after preincubation with 20 wt% water (Fig. S8, supporting information) . The contribution of amid bonds of ODPs to increase the water uptake of hydropobic polymers has previously been noted also in multiblock copolymers [21] . Along with the break up of prexisting H-bonding upon water diffusion in OBMD, an increased molecular mobility of drug molecules and fast release in nanosized polymer matrices can be concluded.
Conclusion
This study has evaluated a general design and fabrication scheme for drug loaded polymer matrices in which computational assisted design and systematic experimental analysis allow tailoring of drug loading and release features for polymeric drug (nano)carriers (Fig. 1) . Drug-polymer affinities can be computationally predicted through molecular dynamics simulation and docking studies, followed by experimental investigation of these interactions in solution as well in solid state to obtain (ideally) molecularly dissolved drug-polymer blends or homogeneously dispersed drug-polymer composites. Under suitable conditions, e.g. solvents as one design parameter, drug loaded matrices can be formed, where molecular interactions enable enhanced drug loading. For those matrices, release profiles may be varied depending on parameters such as carrier size/shape, competition in intermolecular bonding and fast or slow degradation of the respective polymer. Conceptually, this methodology may be applied to various drug-polymer combinations, considering that results of one study may not necessarily allow an extrapolation to other materials. While MD simulations and docking studies may predict interactions between moieties at computationally derived conformations of the polymer chain, it requires processing technologies for experimental evaluation, in which high chain mobility will actually be possible to adapt such advantageous conformations. As computational studies often employ conditions that cannot directly be related to experimental parameters, the experimental proof remains decisive to conclude on the potential of a material to provide enhanced drug -polymer interaction.
As an exemplary material, OBMD has here been investigated based on the hypothesis of enhanced H-bonding with DXM. Through a processing route that enabled such interactions during carrier preparation, the encapsulation efficiency and drug loading of the nanocarriers has been strongly enhanced compared to PLGA. As modelling and experimental data strongly correlated, it is likely that the chosen set-up has predictive power that would enable screening e.g. of a larger variety of depsipeptides differing in their side chains in order to elucidate an optimum matrix candidate for controlled release of a given drug molecule in an efficient manner.
